|
|
Article: Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show.
- Article from:
- PR Newswire
- Article date:
- November 8, 2007
CopyrightCOPYRIGHT 2007 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NEW YORK, Nov. 8 /PRNewswire/ -- Total daily dosages of milnacipran 100 mg and 200 mg demonstrated statistically significant and clinically meaningful improvements in both pain and other core symptoms associated with fibromyalgia syndrome (FMS), according to Phase III data presented this week at the 2007 American College of Rheumatology meeting in Boston, MA. The therapeutic effects of milnacipran among responders in a six-month study were sustained for up to one year in a double-blind extension trial.
(Logo: http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO )
Although widespread chronic pain is the defining characteristic of FMS, it typically ...